AAAAI logo

Home

 Allergy & Asthma Disease Management Center
Funded by an educational grant from sanofi-aventis US


Ask the Expert Current Literature Quiz of the Month Allergy/Respiratory Digest CME Article Meetings/Calendars AAAAI Educational Resources Other Links Comments/Suggestions



September 2008 QUIZ OF THE MONTH . . .

There has been considerable interest in the use of omalizumab, a monoclonal anti-IgE antibody, in the treatment of persistent asthma. Which one of the statements below about omalizumab treatment is true?

  1. It results in a significant decrease in the serum total IgE levels
  2. It does not lead to a decreased expression of the high affinity IgE receptor (Fc epsilon RI) on basophils and mast cells
  3. It is indicated for the treatment of severe, uncontrolled asthma
  4. It is as effective in asthma patients with normal serum IgE levels as in those with moderately elevated serum IgE levels
  5. It is contraindicated in asthma patients receiving allergen immunotherapy



Think you have the answers?

Click here to find out if you're right!

<== Back



Please tell us what you think of this site.